Phio Pharmaceuticals Corp - PHIO STOCK NEWS

Phio Pharmaceuticals (NASDAQ: PHIO), a clinical-stage biotechnology company developing INTASYL® siRNA gene silencing technology for cancer treatment, has appointed David H. Deming to its Board of Directors effective February 19, 2025. Deming will serve on the Board's Nominating Committee, bringing the total board membership to 6 directors, with 5 being independent.

Deming brings over 30 years of experience in investment banking and asset management, including 27 years at JP Morgan where he led the Health Group in investment banking for 12 years. He later joined Integrated Finance , where he developed the SmartNest 401(k) asset allocation product, which was subsequently acquired by Dimensional Fund Advisors in 2010.

Phio Pharmaceuticals (NASDAQ: PHIO) announced its participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series. The company's CEO and Chairman, Robert Bitterman, will present on February 4, 2025, at 2:00 pm EST, discussing their INTASYL siRNA technology and ongoing clinical trial of PH-762 for skin cancer treatment.

The presentation will include a live Q&A session, with a replay available on Renmark Financial Communications' website. Phio is a clinical-stage biotechnology company developing therapeutics using their INTASYL siRNA gene silencing technology, aimed at enhancing immune cells' effectiveness in fighting cancer cells.

Phio Pharmaceuticals (NASDAQ: PHIO), a clinical-stage biotechnology company, has announced its participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series scheduled for January 29, 2025, at 2:00 pm EST.

During the presentation, Robert Bitterman, CEO and Chairman of the Board, will showcase the company's proprietary INTASYL siRNA technology and provide updates on their ongoing clinical trial of PH-762 for treating skin cancers. The INTASYL technology is designed to enhance the effectiveness of immune cells in fighting cancer cells.

Stakeholders, investors, and interested parties are invited to attend this live virtual event. A replay will be available on the Renmark Financial Communications website. Participants are advised to use the latest version of Google Chrome for optimal connectivity.

Phio Pharmaceuticals (NASDAQ: PHIO) has closed a $1.83 million registered direct offering of 610,000 common shares at $3.00 per share, along with concurrent private placement warrants for 1,220,000 shares at $3.00 exercise price, expiring in 24 months. Since December 2024, the company has raised total gross proceeds of approximately $12.08 million, including $9.15 million from offerings and $2.9 million from warrant exercises.

The funds will support working capital and development costs for PH-762's Phase 1b clinical trial treating cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma. Additionally, proceeds will advance development of PH-894, targeting BRD4 protein in solid tumors. H.C. Wainwright & Co. served as the exclusive placement agent for the offering.

Phio Pharmaceuticals (NASDAQ: PHIO) has announced a $1.83 million registered direct offering priced at-the-market under Nasdaq rules. The company will sell 610,000 shares of common stock at $3.00 per share. Additionally, in a concurrent private placement, Phio will issue unregistered warrants to purchase up to 1,220,000 shares of common stock at an exercise price of $3.00 per share, exercisable upon issuance and expiring in 24 months.

The offering, expected to close around January 17, 2025, is being exclusively placed by H.C. Wainwright & Co. The net proceeds will be used for working capital and general corporate purposes. The common stock shares are being offered under a shelf registration statement, while the warrants are being issued through a private placement under Section 4(a)(2) of the Securities Act.

Phio Pharmaceuticals (NASDAQ: PHIO) has announced a $2.5 million registered direct offering priced at-the-market under Nasdaq rules. The company will sell 833,335 shares of common stock at $3.00 per share. Additionally, in a concurrent private placement, Phio will issue unregistered warrants to purchase up to 1,666,670 shares of common stock with an exercise price of $3.00 per share, exercisable upon issuance and expiring in 24 months.

H.C. Wainwright & Co. is serving as the exclusive placement agent. The offering is expected to close around January 15, 2025. The company plans to use the net proceeds for working capital and general corporate purposes. The common stock shares are being offered through a shelf registration statement, while the warrants are being issued in a private placement under Section 4(a)(2) of the Securities Act.

Phio Pharmaceuticals (NASDAQ: PHIO) has announced a $3.19 million registered direct offering priced at-the-market. The company will sell 1,063,670 shares of common stock at $3.00 per share. Additionally, in a concurrent private placement, Phio will issue unregistered warrants to purchase up to 2,127,340 shares of common stock at an exercise price of $3.00 per share, exercisable upon issuance with a 24-month expiration.

The offering, expected to close around January 15, 2025, is being conducted with H.C. Wainwright & Co. as the exclusive placement agent. Phio intends to use the net proceeds for working capital and general corporate purposes. The common shares are being offered under a shelf registration statement, while the warrants are being issued through a private placement under Section 4(a)(2) of the Securities Act.

Phio Pharmaceuticals (NASDAQ: PHIO) announced positive results from the second cohort of its Phase 1b clinical study of PH-762. The study evaluates the safety and tolerability of intratumoral PH-762 in various skin cancers. Two patients with cutaneous squamous cell carcinoma achieved complete response (100% tumor clearance) at Day 36. Among other patients in the second cohort, one showed partial response (90% tumor clearance) and another had stable disease.

The trial included 7 patients total, with 6 diagnosed with cutaneous squamous cell carcinoma and 1 with metastatic melanoma. Importantly, no dose-limiting toxicities or clinically relevant treatment-emergent adverse events were reported, and the intratumoral injections were well tolerated. The study continues to enroll patients to assess higher dose concentrations of PH-762.

Phio Pharmaceuticals (NASDAQ: PHIO) announced the publication of research on RXI-231, an INTASYL compound designed to treat hyperpigmentation, in Clinical, Cosmetic and Investigational Dermatology's December 2024 issue. The study demonstrates that RXI-231 effectively reduces tyrosinase (TYR) gene expression and melanin content in human melanocytes and 3D epidermal cultures.

The research shows that applying RXI-231 every other day visibly reduced pigmentation in 3D epidermal cultures. Testing using the MatTek EpiDerm Skin Irritation model confirmed the compound's non-irritant profile. While additional clinical testing is required, RXI-231 shows promise for treating hyperpigmentation disorders.